The file's text, extracted by GovTribe without its formatting.
SOURCES SOUGHT NOTICE 36C24524Q0625
The Network Contracting Office 5 is conducting this Sources Sought to identify contractors who possess capabilities to provide the services described in the Statement of Work below for Radiopharmaceuticals.
As permitted by the FAR Part 10, this is a market research tool being utilized for the informational and planning purposes. Your responses will assist the Government in the development of its acquisition strategy.
Response is strictly voluntary – it is not mandatory to submit a response to this notice to participate in formal RFQ process that may take place in the future. However, it should be noted that information gathered through this notice may significantly influence our acquisition strategy. All interested parties will be required to respond separately to any solicitation posted as a result of this sources sought notice.
Respondents will not be notified of the results of the evaluation. We appreciate your interest and thank you in advance for responding to the sources sought.
This service will be implemented using the North American Industry Classification System (NAICS) Code 325412.
NOTES
All Capability Statements/Responses to this Sources Sought Notice shall be submitted via email only to kenneth.dougherty@va.gov. Telephone, Fax, or any other form of communication inquiries will not be reviewed or accepted. Responses to this Sources Sought Notice must be received no later than June 24, 2024 at 3:00 p.m. (Eastern Standard Time). This Sources Sought Notice may or may not assist the VA in determining sources only. A solicitation is not currently available. If a solicitation is issued, it may or may not be announced at a later date, and all interested parties shall respond to that solicitation announcement separately from the responses to this Sources Sought Notice.
DISCLAIMER
This Sources Sought Notice is issued for information and planning purposes only and does not constitute a solicitation. All information received in response to this Sources Sought Notice that is marked a proprietary will be handled accordingly in accordance with (IAW) Federal Acquisition Regulation (FAR) 15.201(e), RFIs may be used when the Government does not presently intend to award a contract, but wants to obtain price, delivery, other market information, or capabilities for planning purposes. Responses to these notices are not offers and cannot be accepted by the Government to form a binding contract. Responders are solely responsible for all expenses incurred associated with responding to this RFI.
INTERESTED & CAPABLE RESPONSES:
NCO 5 is seeking responses from businesses that are interested in this procurement and consider themselves to have the resources, rights, and capabilities necessary to provide these services. Please respond with your:
1. Business name (including Unique Entity ID (SAM.gov), business type, socio-economic status (e.g., Veteran-Owned, Woman-Owned, Disadvantaged Small Business, 8(a), etc.), person of contact (including telephone number & email address).
1. Capability statement
1. GSA Contract number, if applicable, to include NAICS
1. Brief summary of categories of professional services that your company can provide.
Applicable Certification(s)/Licenses
Statement of Work
RADIOPHARMACEUTICALS
DESCRIPTION
The Contractor shall provide and deliver radiopharmaceuticals to the Nuclear Medicine Section, Radiology Service at the Veterans Affairs Medical Center (VAMC) in DC, MD, and WV VAMCs. Deliveries shall be made, Monday thru Sunday on a scheduled time from a given list of radiopharmaceuticals. The Contractor shall be able and/or capable of providing emergency orders on demand during normal duty hours and after normal duty hours.
DELIVERY
The Contractor shall deliver the first shipment of daily radiopharmaceuticals orders needs to be delivered by 6:00am, second shipment by 10:00am and third shipment by 2:00pm.
All emergency orders for radiopharmaceutical doses will be placed by a nuclear medicine staff technologist on an emergency need basis. The contractor will deliver all emergency Radiopharmaceuticals doses within two hours of the dose being ordered to the Nuclear Medicine Department.
Due to the demands of the Medical Center care requirements, there shall be no restriction to the number of orders which may be placed by VA, nor the number of deliveries required per day Mon- Fri 630am - 430pm.
The Contractor shall supply a standing order of bulk LEU Technetium 99m in the amount of eighty (80) millicuries calibrated for 8 am and one hundred (100) millicuries calibrated for 4pm Mon-Fri and for Saturday and Sunday one hundred (100) millicuries with a calibration time of 8am and 4pm unless cancelled by the Contracting Officer’s Technical Representative (COTR) or designee.
The contractor shall provide capability for online/web ordering of all radiopharmaceuticals.
A daily packing slip should accompany all Radiopharmaceutical shipments to the Nuclear Medicine Department for all orders placed. The packing slip shall include a bar code that’s compatible and also be able to be scanned into the Nuclear Pharmacy Management System (NMIS) for tracking purposes. The delivery order shall specify contract item (s) and quantity, time (s) of delivery.
The contractor will calibrate all Radiopharmaceutical doses to ensure proper activity ranges of +/-10 percent of the specified ordered dose based on specific requirements provided by the Nuclear Medicine Department based on guidelines outlined in 10 CFR Part 35. The Contractor will ensure that all Radiopharmaceuticals doses provided are compound and calibrated by or under the supervision of a certified pharmacist.
The contractor shall provide any training or education required to meet commercial standards related to use of radiopharmaceuticals to all staff Nuclear Medicine Technologists stationed at VAMCs.
Description of Supplies
| Item No. |
| Name |
| Manufacturer Part Number (MPN) |
| 1 |
| Tc-99m Sestamini UD, Dose 1-30 mCi |
| 102994 |
| 2 |
| Tc-99m Tetrofosmin UD, Does 1-30 mCi |
| 103006 |
| 3 |
| Tc-99m NaTcO4 MD, mCi |
| 102983 |
| 4 |
| Tc-99m NaTcO4 UD mCi, Dose 1.30 mCi |
| 102984 |
| 5 |
| Tc-99m Macro Aggregated Albumin UD *, Dose 1-7 mCi |
| 102970 |
| 6 |
| Tc-99m Mebrofenin UD, Dose 1-8 mCi |
| 102974 |
| 7 |
| Tc-99m Mebrofenin/Choletec, Dose 5 mCi |
| 102974 |
| 8 |
| Tc-99m Mertiatide UD *, Dose 1-10 mCi |
| 102980 |
| 9 |
| Tc-99m Oxidronate UD *, Dose 1.25 mCi |
| 102986 |
| 10 |
| Tc-99m MAA reduced particle, Dose 1-7 mCi |
| 103728 |
| 11 |
| Tc-99m sulfur colloid egg substitute, Dose 1 mCi |
| 108001 |
| 12 |
| Tc-99m sulfur colloid egg, Dose 1 mCi |
| 108001 |
| 13 |
| Tc-99m sulfur colloid UD, Dose 1 mCi |
| 103003 |
| 14 |
| Tc-99m Pyrophosphate UD, Dose 1-30 mCi |
| 102991 |
| 15 |
| Tc-99m Filtered Sulfur Colloid UD, Dose 2 mCi |
| 102943 |
| 16 |
| Tc-99m Pentetate (Aerosol) UD, Dose 40 mCi |
| 102990 |
| 17 |
| Tc-99m Lymphoseek UD, Dose 500 uCi |
| 102967 |
| 18 |
| Tc-99m MDP, Dose 25 mCi |
| 102977 |
| 19 |
| Tc-99m Ceretec Tagged WBC Scan, UD |
| 103012 |
| 20 |
| Tc-99m Cardiolite (sestamini) UD, Dose 20 mCi |
| 102994 |
| 21 |
| I-123 USP Nal 200 uCi Cap, CAP 200iCi |
| 102338 |
| 22 |
| I-123 lobenguane Sulfate UD, Dos 10 mCi |
| 102330 |
| 23 |
| I-131 USP Nal DX Cap mCi * (Base), Dose 1-6 mCi |
| 102366 |
| 24 |
| I-131 USP Nal DX Cap mCi (each additional mCi) * (mCi) |
| 102366 |
| 25 |
| I-131 USP Nal DX Cap uCi * |
| 102367 |
| 26 |
| I-131 USP Nal TX Cap * (Base) Dose 1-6 mCi |
| 102372 |
| 27 |
| I-131 USP Nal TX Cap (each additional mCi) * (mCi) |
| 102372 |
| 28 |
| In-111 Autologous WBC Suspension * 1-25 mCi |
| 102410 |
| 29 |
| Macro Aggregated Albumin Vial * |
| 102659 |
| 30 |
| Mebrofenin Vial |
| 102574 |
| 31 |
| Oxidronate Vial * |
| 102635 |
| 32 |
| Sincalide Vial * |
| 102767 |
| 33 |
| Sincalide Solution UD, Dose 1.55-2.1 ug |
| 34 |
| Penetetate Vial * |
| 102653 |
| 35 |
| I123 loflupane, Dose 10 mCi |
| 108640 |
| 36 |
| UltraTag Vial, Vial |
| 103080 |
| 37 |
| Tc-99m Tilmanocept, Dose up to 1 mCi |
| 103931 |
| 38 |
| F-18 FDG UD, Dose 1-15 mCi |
| 102192 |
| 39 |
| Ga68 Illuccix, Dose 1-5 mCi |
| 108467 |
| 40 |
| Ga68 Locametz, Dose 3-7 mCi |
| 41 |
| Ga68 NetSpot, Dose 5 mCi |
| 105765 |
| 42 |
| Cu64 DetectNet, Dose 4 mCi |
| 107858 |
| 43 |
| F-18 NaF UD, Dose 1015 mCi |
| 102204 |
| 44 |
| Ga-67 Gallium Citrate UD, Dose 4-8 mCi |
| 102279 |
| 45 |
| 1-131 USP NAI TX Cap, Dose 10-200 mCi |
| 102372 |
| 46 |
| In-111 Pentetreotide UD, Dose 6 mCi |
| 102400 |
| 47 |
| In-111 WBC Blood Heparin, Kit |
| 102409 |
| 48 |
| TI-201 Thallous Chloride UD, Dose 1 & 3 mCi |
| 103039 |
| 49 |
| Ra-223 Dichloride (Xofigo), UD |
| 102692 |
| 50 |
| Tc-99m Pentetate (DTPA) |
| 51 |
| I-123 USP Nal 100 uCi Cap |
| 52 |
| Tc-99m Mertiatide (MAG3) |
| 53 |
| In-111 Autologous WBC Suspension |
| 54 |
| Tc-99m Pyrophosphate (Pyrolite) |
| 55 |
| Tc-99m Mebrofenin UD (choletec) |
| 57 |
| Tc-99m Oxidronate UD (HDP) |
| 58 |
| Tc-99m Sestamibi UD (Cardiolite) |
| 59 |
| Tc-99m sulfur colloid UD |
| 60 |
| Tc-99m Tetrofosmin (Myoview) |
| 61 |
| Tc-99m Exametazime (HMPAO) - Ceretec |
| 63 |
| 10mCi Cobalt57 Sheet Source |